\
&
Contact us
\
&
Contact us
This was 11 months ago
LocationOnline
ProgrammesOn 17 and 18 December, the European Climate, Infrastructure and Environment Executive Agency (CINEA) and the European Commission's Directorate-General for Climate Action (DG CLIMA) are hosting an info day to present the key features and award criteria of the upcoming Innovation Fund 2024 Call (IF24 Call) and the Innovation Fund 2024 Battery call (IF24 Battery), and present the lessons learned from previous calls to demonstrate best practices.
More information and registration here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
